Clinical Trial Update: OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Overactive Bladder in Pediatric Patients (12 to 17) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating onabotulinumtoxinA for urinary incontinence due to overactive bladder in pediatric patients aged 12 to 17 was terminated; results poste…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Overactive Bladder
• Urinary Incontinence

Drugs mentioned

• OnabotulinumtoxinA (botulinum toxin type A)

Snippet

Sponsor: Allergan | Conditions: Urinary Incontinence, Urinary Bladder | Phase 3 | Status: TERMINATED | Results posted: 2022-12-28